/Companies

Bellicum Pharmaceuticals, Inc.

Acquired

Houston, US · 5 known investors

Find your way into Bellicum Pharmaceuticals, Inc.

Sign up to see every warm intro you have to Bellicum Pharmaceuticals, Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Bellicum Pharmaceuticals, Inc. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by The University of Texas MD Anderson Cancer Center February 2024 · $8.1M ($8.1 million in cash for substantially all assets) · source ↗

Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.

Founders & leadership

DM
David M. SpencerFounder
KM
Ken MoseleyExecutive
TJ
Thomas J. FarrellExecutive
AM
Annemarie MoseleyExecutive
JS
Joseph SenesacExecutive

Board

KMKevin M. Slawin
Kevin M. SlawinFounderFounder and Managing Partner at Rapha Capital Management, LLC
JF
James F. BrownBoard director
FM
Frank McGuyerBoard director
DK
Dennis K. StoneBoard director

Investors · 5

Reported raises · per SEC filings

Form D private placements

$114.2M disclosed across 2 rounds · 2011–2014

▶$94.4MraisedSep 2014 · 76 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David M. SpencerExecutive Officer
  • Annemarie MoseleyExecutive Officer
  • Kevin M. SlawinDirector
  • Dennis K. StoneDirector
  • James F. BrownDirector
  • Frank McGuyerDirector
  • Ken MoseleyExecutive Officer
  • Thomas J. FarrellExecutive Officer, Director
Offering amount
$94.4M
Amount sold
$94.4M
Sales commissions
$3.1M
Placement agents
Jefferies LLC
First sale
Aug 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19.9MraisedMar 2012 · 21 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ken MoseleyExecutive Officer
  • Thomas J. FarrellExecutive Officer, Director
  • James F. BrownDirector
  • Annemarie MoseleyExecutive Officer
  • Joseph SenesacExecutive Officer
  • Frank McGuyerDirector
  • David M. SpencerExecutive Officer
  • Dennis K. StoneDirector
  • Kevin M. SlawinExecutive Officer, Director
Offering amount
$25M
Amount sold
$19.9M
Minimum investment
$1M
First sale
Nov 2011
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

4 people who came through Bellicum Pharmaceuticals, Inc. went on to found or lead other companies.

Frequently asked questions

What does Bellicum Pharmaceuticals, Inc. do?
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
Who founded Bellicum Pharmaceuticals, Inc.?
Bellicum Pharmaceuticals, Inc. was founded by David M. Spencer.
Who are Bellicum Pharmaceuticals, Inc.'s investors?
Bellicum Pharmaceuticals, Inc.'s investors include Avoro Capital Advisors, Foresite Capital, RA Capital, Rapha Capital Management, LLC, Solasta Ventures.
How much funding has Bellicum Pharmaceuticals, Inc. raised?
Bellicum Pharmaceuticals, Inc. has disclosed $114.2M raised across 2 rounds.
Where is Bellicum Pharmaceuticals, Inc. headquartered?
Bellicum Pharmaceuticals, Inc. is headquartered in Houston, US.